Grail
Prix: 59.85Entreprise et modèle économique
Grail is a healthcare company focused on early cancer detection through advanced genomic testing. Its core products include multi-cancer early detection tests that analyze blood samples to identify various types of cancer at an early stage. The company primarily generates revenue from the sale of these diagnostic tests, targeting both healthcare providers and patients. Grail operates in the diagnostics segment of the healthcare industry, emphasizing innovation in cancer screening technologies.
Profil d’investissement
The investment profile of Grail suggests it may be more suitable for value investors due to its current financial challenges and lack of dividends. The stock's volatility and recent performance indicate a higher risk, which may not appeal to growth-focused investors. A balanced approach could be considered, but the overall outlook leans towards caution.
Métriques fondamentales (expérimental)
- BPA (TTM) — bénéfice par action des 12 derniers mois, $
- -10.37 Risque
- Chiffre d’affaires QoQ — croissance trimestrielle du chiffre d’affaires
- -6.4% ↓
- Surprise BPA
- 17.1% meilleur que prévu
- Volatilité 20 j
- 4.9% stable
Suivre dans le portefeuille
Graphique des prix
| Date | Avant | Après | Raison |
|---|---|---|---|
| 2026-06-03 02:42 | Conserver | Vendre | scenario_deterioration |
| 2026-06-01 02:39 | Vendre | Conserver | Weak fundamentals and high volatility raise significant concerns. |
| 2026-05-08 15:27 | — | Vendre | Weak fundamentals and high volatility raise significant concerns. |
| Date | Analyste | Action | Objectif | Prix alors |
|---|---|---|---|---|
| 2026-06-05 06:33 | Goldman Sachs | Mettre à jour | — → 60 | 66.55 |
| 2026-05-06 11:22 | Piper Sandler | Objectif relevé | 54 → 56 | 54.4 |
| 2026-05-06 10:47 | Robert W. Baird | Objectif abaissé | 82 → 70 | 54.4 |
Rien pour le moment